IL13RA2 and malignant glioma: A phase I clinical trial (NCT02208362) is currently underway to evaluate the safety and optimal dosing of CAR-T immunotherapy targeting the interleukin-13 alpha 2 receptor (IL13Rα2) for the treatment of patients with relapsed or refractory malignant glioma.